Explore every episode of the podcast Business Of Biotech
| Title | Pub. Date | Duration | |
|---|---|---|---|
| Pivoting To RNA With Circio's Dr. Erik Digman Wiklund | 02 Sep 2024 | 01:04:47 | |
We love to hear from our listeners. Send us a message. This week, it’s another “Business of Biotech-meets-Business-of-RNA” takeover with Circio CEO Erik Digman Wiklund, Ph.D. and guest co-host Anna Rose Welch of Advancing RNA. While Circio’s legacy is in cancer immunology (it still boasts a cancer vaccine candidate targeting KRAS driver mutations), the company made a bold pivot, of sorts, when it committed headlong to the circular RNA future. Now, it’s in the throes of fine-tuning a platform for the development of novel circRNA medicines for rare disease, vaccines, and cancer. On this episode of the Business of Biotech, we go deep inside the story behind the pivot, we explore the RNA therapeutic platform-versus-product appetite among biotech investors, and Dr. Digman Wiklund shares insights into the challenges his company overcame to enable such a dramatic shift in focus. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| mRNA Upstarts With Radar Therapeutics' Sophia Lugo and Eerik Kaseniit, Ph.D. | 26 Aug 2024 | 01:03:07 | |
We love to hear from our listeners. Send us a message. Guest co-host Anna Rose Welch of Advancing RNA fame joins us on this week’s Business of Biotech podcast for a conversation with the leaders of RNA upstart Radar Therapeutics. The company’s co-founders, Eerik Kaseniit, Ph.D. (CSO & President) and Sophia Lugo (CEO), are making waves in the mRNA therapeutics space on the heels of the invention of a precision-expressed mRNA technology that laid bare the path to Radar’s inception. On this episode, we dig into that science, why it’s timely, and how it fits into today’s mRNA therapeutics landscape. We also go deep on how Kaseniit and Lugo went about navigating the complexities of biotech formation, leaning into their networks andbuilding up a team—and each other—along the way. Their work is paying off, as the fast-growing company is attracting gobs of investor and big bio attention. For more on the technology Radar is bringing to bear, read Kaseniit and Lugo’s recent byline at Cell & Gene. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| C&G Regulatory Guidance with Lineage Therapeutics' Brian Culley | 24 Jun 2024 | 01:04:02 | |
We love to hear from our listeners. Send us a message. When we last caught up with Brian Culley, CEO at Lineage Cell Therapeutics, it was January, 2021. A pandemic was raging. His company was moving mountains to keep its OpRegen dry AMD clinical trial together, and did so despite lockdowns that kept a largely aged patient population from setting foot anywhere near a healthcare clinic. Lineage emerged stronger, signing a collaboration and license agreement with Roche and Genentech later that year. In May of this year, it doubled down on the commitment with a new services agreement with Genentech to support the OpRegen program. All this, while simultaneously progressing its OPC1 spinal cord injury program into Phase 2 and laying the clinical groundwork for programs in hearing loss, vision loss, and neurologic indications. On his long-overdue return to the Business of Biotech, Culley opens up on how the company addressed struggling programs, wrestled manufacturing control issues and delivery inefficiencies in its spinal cord program to the ground, and maintained control of its regulatory progress along the way. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Oncology Discovery Advances With AbbVie's Steve Davidsen, Ph.D. | 10 Oct 2022 | 00:40:14 | |
We love to hear from our listeners. Send us a message. AbbVie VP of Oncology Discovery Research Steve Davidsen, Ph.D. is a living, breathing timeline of the company's cancer research and development efforts. He got his start with the company— Abbott at the time— way back in 1986. As such, he's charted the adoption of multiple advanced technologies that have contributed to the realization of dozens of molecular weapons in the fight against cancer. On this episode of the Business of Biotech, Dr. Davidsen shares the latest on AbbVie's adoption of computational biology and how it's contributing to discovery and development efficiencies, why he's an AbbVie "lifer," how he manages and motivates a large team of research scientists, and a whole lot more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| IND For TIL Therapy With Obsidian Therapeutics' Paul Wotton, Ph.D. | 03 Oct 2022 | 00:47:28 | |
We love to hear from our listeners. Send us a message. On this episode of The Business of Biotech, Obsidian Therapeutics CEO Paul Wotton, Ph.D. takes us behind the scenes to reveal what precipitated the FDA's clearance of its IND application for a novel, engineered tumor-infiltrating lymphocyte therapy called OBX-115. Learn how the company navigated the regulatory path for a first-of-its-kind biologic therapy developed in partnership with the University of Texas MD Anderson Cancer Center that Dr. Wotton says, should it succeed, will eliminate the patient risk associated with concomitant IL2 therapy and improve clinical outcomes for certain patients with metastatic melanoma. We also get an update on outcomes from Obsidian's unique approach to solving COVID-19 challenges covered on episode 9 of the Business of Biotech. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Regenerative Wound Care With BioStem Technologies' Jason Matuszewski & Andrew VanVurst | 26 Sep 2022 | 01:01:16 | |
We love to hear from our listeners. Send us a message. Here's the story of BioStem, it's young founders, and how they reached commercial status in short order with a portfolio of proprietary regenerative wound care products developed from perinatal tissue. Fueled by a personal story of resilience and inspiration, Jason Matuszewski (CEO) and Andrew VanVurst (COO) built a company that's developed a local microenvironment activation platform drawing on a combination of small molecules, cytokines, and growth factors to promote tissue repair and regrowth. The company's internal development and cGMP manufacturing facilities have already yielded three approved products poised to change the paradigm for diabetic, traumatic, and other wound care. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Epigenomic Programming With Omega Therapeutics' Mahesh Karande | 19 Sep 2022 | 01:01:45 | |
We love to hear from our listeners. Send us a message. Using computational biology to hasten the effort, Omega Therapeutics' plan is to "coopt nature's universal biological operating system for gene control and cell differentiation." On this episode of the Business of Biotech, we dig into exactly what that means. We also explore the company's preclinical ambitions, which are diverse, targeting regenerative, multigenic/immunologic, oncologic, and monogenic indications. Omega is leaning heavily into computational biology along the way, having mapped what CEO Mahesh Karande characterizes as 95% of the IGD landscape. Learn how Karande intends to maintain momentum on this episode of the Business of Biotech. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| IDO Target Perseverence With IO Biotech's Mai-Britt Zocca, Ph.D. | 12 Sep 2022 | 00:37:53 | |
We love to hear from our listeners. Send us a message. Under the leadership of Mai-Britt Zocca, Ph.D., IO Biotech is advancing novel, immune-modulating cancer therapies targeting IDO (indoleamine 2,3-dioxygenase). Though promising, the target fell out of favor after some high-profile misses – most notably Merck's Phase 3 failure with pembrolizumab in 2018. But Immunome's dual mechanism of action is renewing interest in the target, and Dr. Zocca is gaining confidence as the company's data grows. On this episode of the Business of Biotech, she shares the approach, how it differs from previous attempts, and how her company is working to advance its programs in the wake of IDO's fall from grace. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Pursuit Of A Universal Flu Vaccine With Longhorn Vaccines & Diagnostics' Jeff Fischer | 05 Sep 2022 | 00:57:09 | |
We love to hear from our listeners. Send us a message. With a unique multi-target approach, what it considers the world's best adjuvant, and a host of learnings from the successes and failures of COVID-19 vaccine efforts, Longhorn Therapeutics is gaining steam in its pursuit of a universal influenza vaccine. On this episode of the Business of Biotech, Longhorn Vaccines & Diagnostics Co-Founder and President Jeff Fischer gives us a transparent look at the science and the partnerships that are giving him cause to believe his company will succeed where so many have failed. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Genetic Testing & Neurodegenerative Disorders With AviadoBio's Lisa Deschamps | 29 Aug 2022 | 00:52:41 | |
We love to hear from our listeners. Send us a message. Lisa Deschamps' story is one of determination and fortitude. She got her start in the life sciences where it begins and ends for many— "carrying the bag" in big pharma sales—then proceeded to crush the odds on her way to the C-suite at Novartis. Today, she's CEO at AviadoBio, a disruptive gene therapy startup prepping an intra-thalamic Frontotemporal Dementia candidate for the clinic with a heavy Series A in its hip pocket. On this episode of the Business of Biotech we get to know Lisa, her company and its therapeutic approach, her advocacy for genetic testing, and how she's applying her determination and fortitude to enabling more women to become life science leaders. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Biotech M&A Anomalies With Allan Shaw | 22 Aug 2022 | 00:49:49 | |
We love to hear from our listeners. Send us a message. While many clinical-stage biopharmas are contracting or holding the line through the current market slump, Portage Biotech leaders Ian Walters, Allan Shaw, and company are making moves. The company recently acquired Tarus Therapeutics and iOx Therapeutics Ltd., extending its pipeline and positioning itself to meet some aggressive investor expectations. On this episode of the Business of Biotech, Shaw dissects the deals, digging into the M&A strategy at Portage and offering advice from the batter's box to leaders of early-stage biotechs. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Observations On Outsourcing With Molecule to Market's Raman Sehgal | 15 Aug 2022 | 01:00:55 | |
We love to hear from our listeners. Send us a message. Raman Sehgal has made a career out of putting his energy— and he's got a lot of it— into building biotech outsourcing companies and the people who make them run. After years spent supporting several from within, he launched ramarketing, a firm dedicated to helping CROs, CDMOs, CPOs, and other providers to the biotech ecosystem build their businesses, in 2009. He's also an international best-selling author (The Floundering Founder), co-founder of life sciences recruitment firm Lead Candidate, and founder & host of the Molecule to Market podcast. On this week's episode of the Business of Biotech, Raman brings us his unique and multifaceted perspectives on the biopharma outsourcing space, the bear biotech markets, and how both are impacting the work of early- and clinical-stage biopharma leaders. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| What's A Biologic Revolution? With Vaxxinity's Mei Mei Hu, J.D. | 08 Aug 2022 | 00:52:43 | |
We love to hear from our listeners. Send us a message. Vaxxinity CEO Mei Mei Hu, J.D. leads a company with some lofty ambitions. The democratization of healthcare, interplanetary colonization, and development of accessible therapeutic vaccines to serve and enable both. Those big-picture visions have helped the company establish itself as a pioneer of the "third biologics revolution." On this week's Business of Biotech podcast, Mei Mei joins me to share Vaxxinity's strategy, what "democratization" and "revolution" really mean, why traditional vaccines and biologic therapies are converging to form the "third biologic revolution," and a whole lot more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| True DEI Value in Biopharma with Arcellx's Rami Elghandour | 17 Jun 2024 | 01:04:08 | |
We love to hear from our listeners. Send us a message. The cell therapy company Arcellx has, by any and every measure, been outperforming its peers. Its stock has rallied on the back of the strong performance of its multiple myeloma candidate, and the promise of its AML, MDS, and solid tumor pipelines is attracting the kind of interest it takes to be in it for the long run. Asked about his company’s rapid rise since taking the helm in 2021, CEO Rami Elghandour cites a few critical and risky decisions, the execution of some specific people on his all-star team, and a relentless commitment to diversity, equity, and inclusion. Before you skepticize, let me assure you: the man brings receipts. As we head into Juneteenth celebrations, and as pride month comes to a crescendo, we’re all seeing plenty of companies putting a DEI foot forward. Much of this is hollow noise. It’s diversity-washing, the DEI equivalent to greenwashing, whereby organizations misrepresent their environmental practices to create the perception of a commitment to sustainability. Arcellx, and Rami Elghandour, are not that. On this episode of the Business of Biotech, Rami shares vivid lessons from the rise of Arcellx and gets specific on how his steadfast commitment to diversity has fueled its takeoff. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Creative Capital Generation With James Thomas Coates, Ph.D. | 01 Aug 2022 | 00:51:00 | |
We love to hear from our listeners. Send us a message. As biotech capital markets continue to restrict access to funding for emerging biopharmas, you might be surprised by how many federal dollars get left on the negotiating table. To that end, James Thomas Coates, Ph.D. and his team at Decisive Point have carved out a niche in the venture capital space. The firm specializes in helping biotech startups realize direct routes to millions of dollars in federal funding from a host of not-so-intuitive federal institutions—NASA, and the US Navy, Air Force, and Army, for instance—and helping them optimize funding from more obvious federal agencies such as DARPA and the NIH. On this episode of the Business of Biotech, Dr. Coates shares strategies and resources for tapping into biopharma capital that's ripe for the taking. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Oligonucleotide Opportunities in DMD with PepGen's James McArthur, Ph.D. | 25 Jul 2022 | 00:36:29 | |
We love to hear from our listeners. Send us a message. Among the more prevalent genetic conditions, Duchenne muscular dystrophy affects an estimated one in 3,500 male births worldwide. It's caused by mutations of the DMD gene, which regulates the production of a protein called dystrophin. Approved DMD treatments haven't demonstrated strong clinical outcomes, but James McArthur, Ph.D. and his team at PepGen are seeking to change that with a pipeline of disease-modifying peptide-conjugated oligonucleotide candidates derived from the company's Enhanced Delivery Oligonucleotide platform. The Business of Biotech caught up with Dr. McArthur at PepGen's Cambridge headquarters to learn more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Changing The Diabetes Care Paradigm With Arecor's Dr. Sarah Howell | 18 Jul 2022 | 00:59:02 | |
We love to hear from our listeners. Send us a message. While renal disease treatment technologies have seen moderate incremental improvements, there hasn't been a step-change advance in diabetes care since the discovery of insulin more than 100 years ago. Working with manufacturers of existing diabetes therapeutics in addition to advancing its own pipeline, Arecor is developing enhanced reformulations of tried-and-true therapeutics like insulin to improve a long-static standard of care. Arecor CEO Sarah Howell, Ph.D. joins the Business of Biotech for a discussion on the company's approach to improving the quality of life for some 200 million insulin-dependent patients worldwide. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Innate Immunity & Mouse Models With LIfT Biosciences' Alex Blyth | 11 Jul 2022 | 00:58:02 | |
We love to hear from our listeners. Send us a message. Serial inventor and entrepreneur Alex Blyth had long held interests in health and science, but losing his mom to pancreatic cancer was the inflection point that launched LIfT Biosciences in 2016. Now, the preclinical company is on a mission to develop the world's first 'off-the-shelf' cell therapy to destroy all solid tumors, irrespective of strain or mutation, beginning with pancreatic cancer. On this episode of the Business of Biotech, Blyth shares the company's scientific approach and progress, and we explore the shortcomings of legacy clinical protocols including the inherent problems and limitations of mouse models. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Antibody Cocktails With Immunome's Dr. Purnanand Sarma | 04 Jul 2022 | 00:47:15 | |
We love to hear from our listeners. Send us a message. Immunome CEO Purnanand Sarma, Ph.D. joins the Business of Biotech for a discussion on precision antibodies and his company's discovery platform, which identifies novel therapeutic antibodies and their antigen targets by leveraging highly educated memory B cells from patients who have learned to fight off their disease. It’s kind of like picking an all-star team of players who have been in the game, and who are well-trained to win. On today's episode we'll learn how they’re discovered, how they’re developed, and how they’re applied in cancer and coronavirus. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Antibody-Cytokine Combinations With Philogen's Dr. Dario Neri | 27 Jun 2022 | 00:44:09 | |
We love to hear from our listeners. Send us a message. Swiss-Italian biopharma company Philogen was co-founded in 1996 by three brothers, all of them PhDs. This unique family affair has fueled the development of an incredibly deep and advanced pipeline of no fewer than ten therapeutic products, most of them in oncology, contributing to 16 active clinical trials, three of them at Phase 3. On this episode of the Business of Biotech, co-founder, CEO, and CSO Prof. Dario Neri shares the incredible story of the company's progress and explains Philogen's approach to delivering bioactive agents to the site of disease using antibodies or small organic ligands, thus increasing therapeutic activity and helping spare normal tissues. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Fibroblasts In Regenerative Medicine with FibroBiologics' Pete O'Heeron & Dr. Hamid Khoja | 20 Jun 2022 | 00:55:47 | |
We love to hear from our listeners. Send us a message. FibroBiologics Chairman, CEO, & Founder Pete O'Heeron shares the journey that led him from clinical care to biopharma entrepreneurship, and he's joined by Chief Scientific Officer Hamid Khoja, Ph.D., who explains the manufacturing technology that's driving the company's exploitation of fibroblasts to develop regenerative therapies for indications ranging from degenerative disk disease and multiple sclerosis to cancer immunotherapies and therapeutics. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Pyxis Oncology's Lara Sullivan, M.D. On Site-Specific ADCs And Change Management | 13 Jun 2022 | 00:58:35 | |
We love to hear from our listeners. Send us a message. To fully appreciate the work Pyxis Oncology is doing in its development of site-specific ADCs for a number of oncological indications under the leadership of Lara Sullivan, M.D., you need to understand the work that shaped her leadership style. On this episode of the Business of Biotech, Dr. Sullivan shares the science and technology driving progress at Pyxis, but she also serves up a master class on change management, honed during her tenure managing high-stakes product portfolios at Pfizer. If you want to be a better leader, don't miss this one. And for more on Dr. Sullivan's journey, read this recent feature story at Life Science Leader magazine. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| The Biotech Beatdown With Allan Shaw | 06 Jun 2022 | 00:46:25 | |
We love to hear from our listeners. Send us a message. On this, the 100th episode of the Business of Biotech podcast, our dear friend, frequent guest, and business of biotech brainiac Allan Shaw joins us to dissect the beleaguered biotech capital markets. We pick apart what's driving sentiment, whether the industry is over-inventoried, what's getting funded , what's not, and why, and what biotech leaders should be doing in an investment landscape marked by hyper-discernment. We also reflect on the podcast journey and celebrate the 100-episode milestone! Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Inflammation & Antibodies with Ampio Pharmaceuticals' Mike Martino, CEO | 30 May 2022 | 00:56:17 | |
We love to hear from our listeners. Send us a message. Ampio Pharmaceuticals is currently weaving the gauntlet of a clinical hold triggered by COVID's disruption to clinical studies of its lead candidate Ampion, and recently launched an independent investigation into that trial and others. On this episode, Ampio Pharmaceuticals chairman and CEO Mike Martino joins the Business of Biotech for a candid discussion on the company, the candidate, the disruption, and the go-forward plan. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Mission-Driven Dementia Funding with DDF's Jonathan Behr | 10 Jun 2024 | 00:55:46 | |
We love to hear from our listeners. Send us a message. If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonathan Behr, Ph.D. He built a distinguished venture capital career on the back of an MIT Ph.D. in biological engineering, having co-founded no fewer than 7 life sciences companies, served on or observed the boards of at least 17, and led investments at Pure Tech Ventures, the JDRF T1D Fund, SV Health investors, and now, the Dementia Discovery Fund, where he's a partner. Drawing from all that experience, this episode of the Business of Biotech delivers a trove of knowledge on biotech corporate finance and entrepreneurship, as well as the interplay between business strategy and influences like regulatory and scientific trends. We focus on the spirited neurodegenerative space, where case studies in investment and regulatory success and missteps abound. Tune in here and subscribe wherever you listen to podcasts! Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| What's Next For COVID Vaccines With Tonix Pharmaceuticals' Seth Lederman, M.D. | 23 May 2022 | 01:06:51 | |
We love to hear from our listeners. Send us a message. As COVID-19 cases climb yet again, the Business of Biotech catches up with Tonix Pharmaceuticals CEO Seth Lederman, M.D. for a conversation on his company's multi-pronged strategy to advance vaccine and therapeutic candidates to address the disease and its variants. In addition to sharing on his journey from academia to industry, Dr. Lederman discusses his company's approach to grabbing its share of the highly competitive, and highly lucrative, vaccine market. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Running Interference: RNAi with Silence Therapeutics' Craig Tooman | 16 May 2022 | 00:30:44 | |
We love to hear from our listeners. Send us a message. Fresh on the heels of his appointment as President & CEO at Silence Therapeutics, Craig Tooman joins the Business of Biotech to share how he applies his finance-minded leadership to steward the advance of the company's deepening pipeline of gene silencing candidates. Tooman also shares insight into the IP and the people responsible for managing that deep pipeline, which spans indications from hematology to cardiovascular disease to rare diseases. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Live Biologics & The Microbiome With 4D pharma's Duncan Peyton | 09 May 2022 | 00:51:08 | |
We love to hear from our listeners. Send us a message. 4D pharma's flagship early-stage clinical candidates are live biotherapeutics, a relatively new class of biologics that seek to impact disease state by modulating the microbiome. CEO Duncan Peyton is leading the effort to understand how the health of the microbiome relates to a wide range of diseases, including immuno-oncology, central nervous system disorders, respiratory disease, auto immune indications, and gastro intestinal disease. 4D pharma is even working on a live biotherapeutic vaccine platform. Join Duncan on this episode of the Business of Biotech as we discuss this new frontier of therapeutic exploration. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Gene Tx For Renal Disease With Purespring CEO Richard Francis | 02 May 2022 | 00:57:15 | |
We love to hear from our listeners. Send us a message. Purespring Therapeutics launched in 2020 on the back of IP developed by renowned kidney researcher Prof. Moin Saleem, who spent decades working on podocytes when podocytes weren’t cool. Just two years later, the company boasts three gene therapy assets and a platform developed expressly to identify new therapeutic targets to address kidney disease. These assets promise to change the "dialysis or transplant" ultimatums associated with kidney disease, where therapeutic innovation has been scarce. Under the leadership of CEO Richard Francis, the young company is operating with the audacious goal to take its therapeutics all the way to the commercial finish line. On this episode of the Business of Biotech, Francis offers a transparent look at the company’s growth strategy and the progress it’s achieved to date. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Fighting Blindness & Funding The Fight With Opus Genetics' CEO Ben Yerxa, Ph.D. | 25 Apr 2022 | 00:46:25 | |
We love to hear from our listeners. Send us a message. Opus Genetics is an early-stage gene therapy company launched just last year and in unique fashion on the back of the patient advocacy group the Retinal Degeneration Fund. Already, its pipeline has developed into three candidates, the lead among them addressing Leber congenital amaurosis. Opus CEO Ben Yerxa, Ph.D. serves in triplicate as CEO at the RD Fund, Foundation Fighting Blindness, and Opus Genetics. His plate is full, but he's a man on a mission. On this episode of the Business of Biotech, Dr. Yerxa shares his story, that of Opus Genetics' unique approach to addressing inherited retinal diseases, and how the company is addressing current development and capacity challenges in the cell & gene manufacturing space. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Gynecological Cancer Therapies with Context Therapeutics' Martin Lehr | 18 Apr 2022 | 00:47:07 | |
We love to hear from our listeners. Send us a message. Context Therapeutics Co-Founder & CEO Martin Lehr shares stories from his self-described "recovery from venture capital," the work his company is doing in gynecological cancers, and how his small company manages a modality-agnostic approach and investigator-sponsored trials across multiple clinical candidates, four of which are in phase 2 clinical trials. We also discuss his "extracurricular" work with BioBreak, Life Science Leader, and Life Science Cares, and why those organizations are important to him personally and professionally. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Commensal Viral Vectors with Ring Therapeutics' Tuyen Ong, M.D. | 11 Apr 2022 | 00:46:52 | |
We love to hear from our listeners. Send us a message. When Tuyen Ong was a child, he and his family escaped Vietnam by boat in the dead of the night, bound for an Indonesian refugee camp. They spent a year in that camp before emigrating to the U.K., where Ong’s underprivileged adolescence found him growing up in the projects of London. Against the odds, Ong worked his way to UCL for an education that culminated with an M.D. Today, he’s CEO of Ring Therapeutics, a promising emerging biotech backed by Flagship Pioneering, the kingmaker behind the rise of Moderna. On this episode of the Business of Biotech, Ong shares on his challenging formative years, the unspoken love between a father and son, facing down racism as a poor Chinese kid in Vietnam and London, and how those experiences shape his leadership at Ring. Oh, and we talk about some really great science, too. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Antibodies For Severe Allergies With IgGenix's Jessica Grossman, M.D. | 04 Apr 2022 | 00:38:55 | |
We love to hear from our listeners. Send us a message. In this wide-ranging discussion, IgGenix CEO Jessica Grossman, M.D. discusses the application of and market opportunity for antibody therapy for severe allergies, the gender gap in the biopharma c-suite, why women work harder than men, what it means to be a female biopharma leader, and IgGenix's approach at isolating and re-engineering allergen-specific IgE antibodies into IgG antibodies designed to alleviate — and possibly prevent — allergic cascade. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Gene Therapies For Ocular Disease With Sparing Vision's Stéphane Boissel | 28 Mar 2022 | 00:56:20 | |
We love to hear from our listeners. Send us a message. Since assuming the President and CEO role at Sparingvision in August, 2020, Stéphane Boissel has been making big moves in the arenas of talent acquisition and IP expansion. Those efforts are securing the company's development of a number of genomic medicines to address inherited retinal disease. On this episode of the Business of Biotech, Boissel shares the company's foundation story and the role venture philanthropy played in it, his strategy for attracting and retaining big-league talent, and the why behind his vigorous allegiance to internal development. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Biotech M&A Trends With Allan Shaw | 21 Mar 2022 | 00:50:03 | |
We love to hear from our listeners. Send us a message. On this episode of the Business of Biotech, Allan Shaw waxes on his expectations for mergers, acquisitions, and collaborative partnership opportunities for new and emerging biotechs in 2022 and beyond. We tackle questions biotech leaders should be asking about intentionality, what's attractive to potential suitors, and why startups that aren't prepared to take a candidate to the finish line have already conceded a major factor in partnership or buyout negotiations. Don't miss Shaw's advice for startup success in a suddenly tumultuous market. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| ADCs Ignited with Daiichi Sankyo Inc.'s Ken Keller | 03 Jun 2024 | 01:04:06 | |
We love to hear from our listeners. Send us a message. Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics space, and it certainly wasn't a player in ADCs. But then, just a few years ago, who was? Fast forward to 2023, and we see an ADC arena that drove nearly $100 billion in M&A, licensing, and partnership deals, and a Daiichi Sankyo that can rightfully lay claim to lighting that fire. In fact, it was our guest on this episode of the Business of Biotech, Ken Keller, Chairman of the Board, President, and CEO at Daiichi Sankyo, Inc. who made the bold move to jump headlong into oncology armed with ADCs that, at the time, weren't exactly the darling of biotech. On this episode, Ken shares the story of his climb from "carrying the bag" all the way to the Big Biotech C-Suite, how and why Daiichi Sankyo pivoted from its roots in cardiovascular therapeutics into Oncology and ADCs, his reflections on the antibody-drug conjugate market, and a whole lot more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Lipid Nanoparticle Gene Coding With SalioGen Therapeutics' Ray Tabibiazar, M.D. | 14 Mar 2022 | 00:50:03 | |
We love to hear from our listeners. Send us a message. This episode of the Business of Biotech is fire. In fact, it's an interview with SalioGen Therapeutics Chairman and CEO Ray Tabibiazar, M.D., whose last name literally translates to "Dr. Fire." Learn how he got that name, what's shaped his technology-agnostic philosophy on therapeutic development, the advantages of a genome engineering technology that leverages proprietary mammal-derived enzymes, rather than viruses, and how SalioGen is possibly carrying forth a pipeline that's 15 candidates deep and addressing eye, liver, heart, lung, bone marrow, and kidney diseases. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| CAR T-cells For Ovarian Cancer with Anixa Biosciences' Amit Kumar, Ph.D. | 07 Mar 2022 | 00:55:33 | |
We love to hear from our listeners. Send us a message. While success has been seen in animal models, solid tumors have proved a vexing challenge for CAR T-cell therapies. On this week's episode of the Business of Biotech, we're joined by Anixa Biosciences Chairman, President, & CEO Amit Kumar, Ph.D. Dr. Kumar shares on the company's progress with a CAR T-cell therapy that aims to attack both tumor cells and the tumor vasculature, in hopes that it might be the first to destroy solid ovarian cancers. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| AI-Driven Biologics With Fountain Therapeutics' William Greene, M.D | 28 Feb 2022 | 00:49:40 | |
We love to hear from our listeners. Send us a message. With its hypothesis-free, target-free, AI-driven drug discovery platform, Fountain Therapeutics is turning the traditional drug discovery pathway on its ear to address a variety of age-related disease. On this week's episode of the Business of Biotech, Fountain CEO William Greene, M.D. joins us to discuss the approach, its rationale, and how the company is applying substantial support from the likes of Eli Lilly, Alexandria Venture Investments, R42 Group, Khosla Ventures, and Nan Fung Life Sciences. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Regulatory Harmonization With Aurion Biotech's Dr. Daniela Drago | 21 Feb 2022 | 00:41:58 | |
We love to hear from our listeners. Send us a message. If you're taking a candidate into clinical trials that will be monitored by multiple international regulatory bodies, this episode is an absolute must-listen. Dr. Daniela Drago , Chief Regulatory Officer at Aurion Biotech, shares her encyclopedic knowledge of the dynamic regulatory harmonization landscape. Along the way, she offers concrete advice on creating multijurisdictional regulatory efficiencies that will smooth your journey through the clinic and beyond. Don't miss this one. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Plant-Based Biologics With iBio's Randy Maddux | 14 Feb 2022 | 00:50:36 | |
We love to hear from our listeners. Send us a message. iBio COO Randy Maddux walks us through the Bryan, Texas-based biopharma's attempt to turn the CHO cell biologic development paradigm on its ear with hydroponically-grown N. benthamiana. His company's FastPharming approach to protein production, he says, could be modularized to speed cycle times and dramatically reduce upstream costs at scales large and small. For its part, iBio is proving out the approach on a host of therapeutic and vaccine candidates for oncological, infectious, and fibrotic diseases. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| NK Cell Therapy Accessibility With Shoreline Biosciences' Dr. Kleanthis Xanthopoulos | 07 Feb 2022 | 00:37:55 | |
We love to hear from our listeners. Send us a message. Shoreline Biosciences CEO Kleanthis Xanthopoulos, Ph.D. joins the Business of Biotech to share the company's strategy for the development, manufacture, and commercialization of off-the-shelf NK (natural killer) cell therapy. On this episode, Dr. Xanthopoulos shares why the cell and gene immunotherapeutic market has underperformed to date, why he believes autologous is not the long-term path forward, and the safety and accessibility advantages he sees in his allogeneic-based, pluripotent stem cell approach. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| A Hybrid mAb Manufacturing Model With John Glasspool | 31 Jan 2022 | 00:45:06 | |
We love to hear from our listeners. Send us a message. Post-operative venous thromboembolism (VTE) is a serious and prevalent post-operative risk that has several contributing factors. John Glasspool, CEO at Anthos therapeutics, is on a mission to address the issue—and a host of other cardiovascular and metabolic conditions—with monoclonal antibodies that inhibit coagulation Factor XI and its activated form XIa. On this episode of the Business of Biotech, Glasspool discusses the advantages and challenges of the hybrid manufacturing approach at Anthos, and how its strategy has enabled phase 1 and 2 clinical studies that have demonstrated an 80% reduction of the rate of VTE in post-operative total knee arthroplasty patients compared to the standard of care (enoxaparin). Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Biotech Capital Markets Forecast With Allan Shaw | 24 Jan 2022 | 00:47:34 | |
We love to hear from our listeners. Send us a message. As Allan Shaw likes to say, "there have never been so many people with their hands out, and there has never been so much money to go around." But how sustainable is this seemingly perennial boom in the biotech capital markets? Will the road go on forever and the party never end, or are there signs of a slowdown on the horizon? Shaw once again joins us to break down the market activity he's seeing, and what he anticipates for early-stage biotech leaders in 2022. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Venture Philanthropy For Type 1 Diabetes With T1D Fund's Katie Ellias | 17 Jan 2022 | 00:46:18 | |
We love to hear from our listeners. Send us a message. The JDRF's T1D Fund is exemplary of an indication-specific advocacy group's aggressive pursuit of a cure through venture philanthropy. Put simply, unlike traditional VC firms who entertain myriad and often diverse pitches from biotech startups, the T1D fund creates financial and advisory incentives for the biotechs in its portfolio to pursue candidates and formalize programs around Type 1 Diabetes therapies. A growing number of the programs the T1D fund is supporting are cell and gene therapies and biologics. Katie Ellias, a managing director at the fund, joins the Business of Biotech to explain the JDRF T1D fund's unique approach, why Type 1 Diabetes is an important and potentially lucrative indication, and how the venture philanthropy model applies to the life sciences startup community. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Precision Approach To Infectious Disease With Locus Biosciences' Paul Garofolo | 10 Jan 2022 | 00:57:04 | |
We love to hear from our listeners. Send us a message. Locus Biosciences CEO Paul Garofolo built his biotech leadership career on the back of an MIS degree, having learned the business from the inside out via the tentacles of the IT networks at companies including Genentech, The Broadlane Group, Valeant Pharmaceuticals and Patheon. On today's episode of the Business of Biotech, Garofolo shares how a technologist's approach has helped shape the effort to develop precision therapeutics for infectious diseases at Locus, the company's decision to build its own cGMP manufacturing facility in Research Triangle, and the massive business opportunity the field addresses in the effort to overcome antibiotic resistance. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Accelerating ADCs with Mythic Therapeutics' Brian Fiske, Ph.D. | 27 May 2024 | 00:56:38 | |
We love to hear from our listeners. Send us a message. Mythic Therapeutics Chief Scientific Officer and co-founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted transition from academia to industry. He calls his many, and sometimes concurrent, early experiences as an MIT Ph.D. student, a Flagship Ventures Fellow, a Bain consultant, a hospital researcher, and a biopharma consultant indiciative of a young man who didn't want to make decisions. In retrospect, it looks more like the perfect preparatory mix for a guy who's leading a company with a unique approach to a white-hot ADC (antibody-drug conjugate) therapeutics market. On this epsiode of the Business of Biotech, get to know Brian as we peel back the layers to expose what's fueling the rapid rise of Mythic's ADC candidate in non-small cell lung cancer. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Bioengineering Human Tissue With Humacyte's Dr. Heather Prichard | 03 Jan 2022 | 00:41:01 | |
We love to hear from our listeners. Send us a message. Humacyte COO Dr. Heather Prichard joins the Business of Biotech for a discussion on the company's pipeline of candidates for the repair, replacement, and reconstruction of human vascular vessels. The company recently scaled the production of its implantable bioengineered human tissues from 10 to 200 per day to meet Phase 3 vascular trauma and arteriovenous access trials. On today's episode, Dr. Prichard shares the company's scale-up story and the science and engineering behind a unique approach to regenerative medicine using human tissue. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| The Top Stories Of 2021 With Allan Shaw | 27 Dec 2021 | 00:45:24 | |
We love to hear from our listeners. Send us a message. Join your host Matt Pillar and guest Allan Shaw for a no-hold-barred retrospective on the year's top stories and trends. From the frontlines of the COVID-19 pandemic to the questionable approval of Aduhelm to leadership instability at the FDA and more, Shaw dissects the year past and predicts how those stories will influence the biotech industry in 2022 and beyond. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| Complete CAR T Manufacturing Control with Cellectis' Steve Doares | 20 Dec 2021 | 00:40:04 | |
We love to hear from our listeners. Send us a message. Cellectis' decision to build and operate its own trans-Atlantic manufacturing facilities was a strategic one. On this week's episode of the Business of Biotech, SVP of U.S. Manufacturing Steve Doares talks internal manufacturing rationale, discusses interoperability between its Paris and Raleigh, N.C. plants, and shares how the company keeps meeting the challenges presented by COVID-fueled supply chain disruptions head-on. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||